Tag Archives: ACC 2023

ACC 2023 | PULSE-AF

ACC 2023 | PULSE-AF

Catheter ablation is an effective treatment for patients with atrial fibrillation (AF) refractory to the standard medical treatment. Verma et al. conducted a global, prospective, multicenter, nonrandomized study in which patients were operated with the PulseSelect system—pulmonary vein isolation using a nonthermal ablation system—and followed-up at 12 months. The system consists in nonthermal ablation, discharging

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable coronary artery disease. The study included 137 patients who underwent coronary angioplasty to the culprit vessel and endovascular imaging (OCT, NIRS/IVUS) to non-obstructive lesions (30%-50%). If their plaque was lipid-rich (defined

ACC 2023 | RENOVATE-COMPLEX-PCI: Intravascular Imaging-Guided vs. Angiography-Guided Complex PCI

Patients with complex coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) have worse clinical outcomes tan patients with non-complex CAD. Several studies have shown that the use of intravascular imaging (IVUS, OCT) have reduced major adverse events vs. angiography guided PCI. However, these studies present limitations both of size, studied population, short term followup

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical risk. The current ACC and AHA guidelines recommend that a Heart Team make the decision for 65 to 80-year-old patients with aortic stenosis.  In low risk patients, fast recovery and short term benefits of TAVR should be weighed

Top